19 Sep 2007 03:00 AM
The Leukemia & Lymphoma Society Is Encouraged By Promising News For Myeloma Patients
Millennium Pharmaceuticals
and Johnson & Johnson have reported that an interim analysis of a large,
randomized, international Phase III trial comparing melphalan-prednisone
(MP) with MP in combination with Velcade(R) (bortezomib) showed that the
patients treated on the Velcade arm did better. These patients, who are not
eligible for a stem cell transplant, experienced statistically significant
benefit in terms of time-to-disease progression, complete response rate,
progression-free survival and overall survival. Patients treated on the MP
arm of the trial have the opportunity to switch over to the Velcade arm.
Detailed results from this trial will be presented at the…
Detailed results from this trial will be presented at the…
